MARKET

NGNE

NGNE

Neurogene
NASDAQ
11.49
+0.72
+6.69%
After Hours: 11.02 -0.47 -4.09% 17:34 04/17 EDT
OPEN
10.75
PREV CLOSE
10.77
HIGH
11.54
LOW
10.46
VOLUME
190.04K
TURNOVER
--
52 WEEK HIGH
74.49
52 WEEK LOW
6.88
MARKET CAP
171.54M
P/E (TTM)
-2.6861
1D
5D
1M
3M
1Y
5Y
1D
NEUROGENE INC - AMENDS AGREEMENT WITH BAKER BROS TO INCREASE NOMINATION THRESHOLD - SEC FILING
Reuters · 6d ago
NEUROGENE : INCREASES NOMINATION THRESHOLD AT WHICH BBA HAS CERTAIN RIGHTS TO NOMINATE ONE PERSON AS DIRECTOR TO 14.9% OF VOTING STOCK
Reuters · 6d ago
Weekly Report: what happened at NGNE last week (0407-0411)?
Weekly Report · 6d ago
Neurogene Is Maintained at Outperform by BMO Capital
Dow Jones · 6d ago
BMO Capital Maintains Outperform on Neurogene, Lowers Price Target to $16
Benzinga · 6d ago
NEUROGENE INC <NGNE.O>: BMO CUTS TARGET PRICE TO $16 FROM $45
Reuters · 6d ago
Weekly Report: what happened at NGNE last week (0331-0404)?
Weekly Report · 04/07 12:14
Short Report: Bears push short interest on Wolfspeed to record highs
TipRanks · 04/06 16:50
More
About NGNE
More
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.
Recently
Symbol
Price
%Change

Webull offers Neurogene Inc stock information, including NASDAQ: NGNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NGNE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NGNE stock methods without spending real money on the virtual paper trading platform.